drug substance postapproval changes guidance: determination of impurity profile equivalence
Published 3 years ago • 4.2K plays • Length 23:25Download video MP4
Download video MP3
Similar videos
-
21:51
safety evaluation of drug substance impurities in generics
-
27:10
overview of post-approval chemistry, manufacture, and controls (cmc) changes to an nda - redi 2020
-
15:42
evaluation of metal impurities in drug substances
-
25:35
application of (q)sar and expert knowledge for ich m7 impurity classification
-
20:18
drug substance quality assessment: best practices (23of27) generic drugs forum 2018
-
1:22:14
overview of the guidance for industry: control of nitrosamine impurities in human drugs
-
39:13
impurities in drug substances/products: global guidances & usp perspective
-
10:57
list of relevant quality guidances & common deficiencies observed during dmf review
-
24:59
modernizing drug substance assessment through kasa
-
12:22
mutagenic impurities from a drug substance perspective: highlights from ich m7 q&a draft document
-
18:05
common issues related to lc and gc methods in type ii dmfs
-
1:21:15
questions and answers on drug master files (dmfs) and drug substances part i
-
20:06
major issues and facilities in drug master files (9/15) global quality
-
25:40
impurity case studies: pharmacology/toxicology (22of28) generic drugs forum – apr. 3-4, 2019
-
14:56
drug substance review - anda (22/28) generic drugs forum 2017
-
22:39
panel discussion – drug master file and drug substance workshop
-
24:23
panel discussion - drug master file and drug substance workshop
-
1:23:05
questions and answers on drug master files (dmfs) and drug substances part ii
-
13:26
establishing impurity acceptance criteria as part of specs for dmfs based on clinical relevance